Since the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s,HIV-related deaths have declined, and the number of individuals living with HIV has increased. [1] [2] [3] Chronic diseases, such as ESRD, have now surpassed opportunistic infections as the leading cause of death among HIV-positive (HIV + ) individuals, and HIV-associated nephropathy is the third leading cause of ESRD among African Americans. [4] [5] [6] [7] [8] [9] [10] Kidney transplantation is now offered as an acceptable treatment option for HIV + ESRD patients and has expanded beyond the scope of clinical trials. Although this marks a new era in the care of the HIV + ESRD patient, experience with HIV + kidney transplantation remains in its relative infancy.
Recently, the largest prospective clinical trial examining outcomes among 150 HIV + kidney transplant recipients reported 3-year patient and graft survival of 88.2% and 73.7%, respectively, which were similar to survival rates among a cohort of unmatched elderly (.65 years) HIV-negative (HIV 2 ) kidney recipients. The median length of follow-up among study participants was 1.7 years (interquartile range [IQR] , 0.7-3), but ,60 patients had 3 years of follow-up. 11 Although these findings are encouraging, concerns remain regarding the high incidence of acute rejection after HIV + kidney transplantation and its possible effect on long-term transplant outcomes. 12, 13 To date no study has examined long-term outcomes or compared HIV + recipients to their appropriately matched HIV 2 counterparts. Furthermore, current practice is on the basis of results from a highly scrutinized clinical protocol used within the prospective National Institutes of Health (NIH) trial. The trial was limited to high-volume centers and involved only 150 study participants, representing a small sample of the .500 HIV + kidney transplants that have been performed in the United States. Going beyond the confines of the NIH trial to study the entire United States experience with HIV + kidney transplantation is necessary to properly assess the generalizability of findings, to provide the power for risk factor estimation, and to allow for comparison with properly matched controls.
To better understand outcomes in this unique patient population, we examined long-term patient and graft survival among the United States HIV + kidney transplant population in its entirety and compared these outcomes with the outcomes of appropriately matched HIV 2 recipients.
RESULTS

Study Population
During the study period, there were 510 HIV + first-time kidney transplants performed (median follow-up: 3. 2 )$30: 18.1% versus 33.3%, P,0.001), and were more often men (79.6% versus 61.0%, P,0.001), African American (71.0% versus 26.5%, P,0.001), infected with hepatitis C virus (HCV) (24.2% versus 5.5%, P,0.001), and receiving maintenance steroids (75.1% versus 66.1%, P,0.001). Moreover, HIV + patients were less likely to receive a kidney from a living donor (27.7% versus 38.4%, P,0.001) and receive anti-thymocyte globulin (ATG) induction therapy (27.8% versus 42.6%, P,0.001) and were more likely to have developed acute rejection post-transplant (17.8% versus 8.8%, P,0.001) compared with the general HIV 2 population (Table 1) . Among the matched cohort, HIV+ recipients were more likely to be men (79.1% versus 63.5%, P,0.001), receive maintenance steroids (77.2% versus 67.0%, P,0.001), and have acute rejection (17.4% versus 10.3%, P,0.001) and were less likely to be obese (BMI$30: 17.1% versus 37.5%, P,0.001) and receive ATG induction (29.5% versus 47.1%, P,0.001) ( Table 1) . patients, and in particular, the increased mortality among this population. Although worrisome, these findings do motivate future studies aimed at examining the survival benefit of kidney transplantation over dialysis among HIV + patients coinfected with HCV. Moreover, efforts to improve long-term outcomes may require modifications of posttransplant processes of care for coinfected HIV + recipients, such as life-long follow-up at a transplant center, as opposed to the more traditional practice of transitioning care to the community. In addition to HCV coinfection, worse outcomes were also seen among HIV + recipients who received kidneys with .10 hours of CIT, whereas the use of kidneys from living donors was associated with improved outcomes.
Worse outcomes among coinfected recipients highlight the negative effect of HCV coinfection in the HIV + kidney transplant population. Our results are consistent with findings from prior studies, which have also demonstrated worse GS and PS among kidney transplant recipients infected with HCV. 11, 14 Importantly, the burden of HCV infection appears to be much greater among HIV + recipients compared with the general HIV 2 kidney transplant population. In fact, we found that .24% of HIV + recipients were coinfected with HCV compared with only 5.5% among the HIV 2 population. Traditionally, HCV infection was not thought to be a modifiable risk factor for graft loss because antiviral treatments lacked effectiveness. More recently, however, newer antiviral treatments for HCV genotype-1 have demonstrated sustained virologic responses .99%, 15, 16 offering the promise of potential cure and attenuation of lower survival rates among HIV kidney transplant recipients coinfected with HCV.
Another potentially modifiable risk factor for outcomes among HIV + recipients was CIT. Our finding parallels results from studies within the general transplant population that have demonstrated an association between prolonged CIT and increased risks for the development of delayed graft function (DGF) and graft loss. [17] [18] [19] [20] We have previously shown that the effect of CIT on outcomes after kidney transplantation is more pronounced among HIV + recipients compared with their HIV 2 counterparts. 21 These findings motivate a focus in clinical practice to reduce CIT in HIV + recipients. Additionally, it is possible that the mechanism for this relationship is the association between CIT and DGF. Management strategies aimed at reducing the effect of DGF on graft outcomes may be prudent. This increased susceptibility to the adverse effects of DGF may be in part explained by the increased risk for CNI nephrotoxic effects among HIV + patients on a ritonavir-boosted protease inhibitor based regimen. 22, 23 Focused attention to transitioning HIV + candidates to integrase inhibitorbased HAART and off protease inhibitor-based HAART may Inferences on the basis of our findings must take into account a number of important limitations. SRTR's data lack granularity with regard to CD4 count, viral loads, infections, and malignancies, factors that are known to influence longterm outcomes among HIV + patients. However, the NIH's protocol used relatively restricted criteria for HIV + ESRD patients to be considered candidates for transplantation, requiring undetectable viral loads and CD4 counts of $200. It is unlikely that there would be major deviations from this protocol in the national data. Moreover, immunosuppressant levels and antiviral regimens are not captured by SRTR data, and as such, it is impossible to determine whether drug interactions between HAART therapy and immunosuppressants led to subtherapeutic drug levels and higher rates of acute rejection and graft loss. Although understanding these interactions would help inform the mechanism of our long-term findings, the absence of these data do not bias our findings in any manner. Finally, the sample sizes available for our subgroup analyses were relatively small and may directly affect the accuracy of our estimates. However, these data represent the HIV + kidney transplant population in the United States in its totality and therefore contribute new and important information about long-term outcomes after kidney transplantation in this unique population. To date, this is the first national study examining outcomes among the entire United States cohort of HIV + kidney transplant recipients and comparing their outcomes to appropriately matched HIV 2 counterfactuals. In comparison with appropriately matched HIV 2 controls, we found similar 5-and 10-year GS and PS among monoinfected HIV + recipients and significantly worse outcomes among HIV + recipients coinfected with HCV. These results are encouraging, but they do suggest caution in transplanting HIV + recipients coinfected with HCV, motivating future studies of survival benefit.
CONCISE METHODS
Data Source
This study used data from the SRTR. The SRTR data system includes data, submitted by the members of the Organ Procurement and Transplantation Network, on all donors, waitlisted candidates, and transplant recipients in the United States. The Health Resources and Services Administration of the US Department of Health and Human Services provides the oversight to the activities of the Organ Procurement and Transplantation Network and SRTR contractors. 
Study Population
Outcome Ascertainment
The primary outcome measures were DCGS, GS, and PS. DCGS was defined as the time from transplantation to graft loss, return to dialysis, or last follow-up with a functioning graft, censored for death. GS was defined as the time from transplantation to graft loss, return to dialysis, last follow-up with a functioning graft, or death. PS was defined as the time from transplantation to death or last follow-up. Death indicators were supplemented by linkage to the Social Security Death Master File; death and graft loss were supplemented by linkage to data from the Centers for Medicare and Medicaid Services. All outcome measures were censored for administrative end of study.
Statistical Analyses Exploratory Data Analyses
Donor and recipient characteristics were compared by HIV status. Continuous variables were analyzed using t tests or Wilcoxon ranksum tests (on the basis of distribution), and categorical variables were examined using chi-squared or Fisher's exact tests of independence (on the basis of sample size).
Survival Analyses
DCGS, GS, and PS were estimated among HIV + recipients using Kaplan-Meier methods, log-rank tests, and Cox proportional hazards models. Risk factors for graft loss and patient death within the HIV + cohort were identified using univariate Cox proportional hazards with statistical significance set at 0.1. The proportional hazards assumption was assessed and verified using time-dependent variables. DCGS, GS, and PS among HIV + recipients were compared with the general, unmatched HIV 2 population and to appropriately matched HIV 2 controls using Kaplan-Meier methods, log-rank tests, and Cox proportional hazards models. HIV + recipients were matched to appropriate HIV 2 counterfactuals 1:10 using iterative, expanded radius matching without replacement and were matched on factors found to be significantly associated with each outcome. The matching algorithm for GS included recipient age and race, HCV infection, CNI-based maintenance immunosuppression, PRA, CIT (for deceased donors only), and transplant year. The matching algorithm for PS included HCV infection, CNI-based maintenance, recipient age and race, and transplant year. Additional covariates were adjusted for as part of sensitivity analyses, and inferences did not change. For simplicity, results from the matched analyses without additional adjustment are reported. 
Sensitivity Analyses
Covariates determined to be significant on exploratory analyses (Table  1) were used to build full multivariate models. Results from these models confirmed inferences reported from the matched (1:10) analyses. Matched control analyses must balance introduction of bias with reduction in variability (i.e., with increasing numbers of controls per patient, more bias is potentially introduced; however, variability is theoretically reduced). Given this, the analyses were performed among four distinct matched cohorts (1:1, 1:3, 1:5, and 1:10); inferences did not change. For the purposes of simplicity, results comparing outcomes among HIV + and HIV 2 kidney transplant recipients are from the 1:10 matched cohort. Finally, multivariate models, adjusting for additional covariates, were built in the 1:10 matched cohort: 1) GS and DCGS models adjusted for recipient age, race, sex, BMI, ATG induction, maintenance steroids, and donor age; and 2) PS model adjusted for recipient sex, BMI, PRA, ATG induction, maintenance steroids, and donor age and CIT; inferences did not change.
